Open AccessEfficacy and safety of adjuvant therapy with nivolumab or placebo in high-risk patients with muscle-invasive urothelial carcinoma after radical surgery: review of the first results of the randomized phase III trial CheckMate 274
Author(s) -
Maria Volkova,
А. С. Ольшанская,
Sergey Kalinin
Publication year - 2021
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2021-17-1-108-119
Subject(s) - medicine , nivolumab , adjuvant , placebo , randomized controlled trial , adjuvant therapy , urothelial carcinoma , immunotherapy , oncology , urology , surgery , chemotherapy , bladder cancer , cancer , pathology , alternative medicine
This article analyzes first results of the randomized phase III clinical trial CheckMate 274 that has demonstrated the advantage of adjuvant immunotherapy with nivolumab, a PD-1 inhibitor, over placebo in high-risk patients with muscle-invasive urothelial carcinoma after radical surgery